5.4.2010 SPEAKER: David Reed, MD, MPH, MBA, Serial Entrepreneur MODERATOR: Zen Chu, Director of Business Development & Wyss Accelerator Fund, Wyss Institute for Biologically Inspired Engineering, Harvard University

Forum Summary

Biomedical innovators planning clinical studies should make sure that their studies prove both effectiveness and value.  Physicians are no longer driving the healthcare market.  Large payers such as insurance companies and health maintenance organizations (HMO’s) are the entities that determine which products will be adopted.  Controlling costs is pivotal if these payers are to be interested in a new device.  Biomedical companies will benefit if they can show that their product keeps patients out of the hospital.  Efficiency and cost effectiveness are becoming increasingly valued.

Post a Comment